Jessica Kay Jeffrey MD MPH, MBA

Addiction, Child & Adolescent Psychiatry

Physician

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Child and Adolescent Psychiatry, 2012 - 2014
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 2009 - 2013
University of California, Los AngelesMBA, Entrepreneurial Studies, 2007 - 2009
David Geffen School of Medicine at UCLAClass of 2009
University of California Berkeley, School of Public HealthMPH, Maternal and Child Health, 2002 - 2004
University of California, Los AngelesB.S., Psychobiology, Summa Cum Laude, 1998 - 2001

Recipient UCLA House Staff Quality Improvement Scholarship, 2013
Recipient American Academy of Child and Adolescent Psychiatry Systems of Care Fellowship, 2013
Recipient American Academy of Child and Adolescent Psychiatry Educational Outreach Award Fellowship, 2012
Recipient American College of Psychiatrists PRITE Fellowship, 2012
Louis Jolyon West Award for Excellence in Psychiatry David Geffen School of Medicine, UCLA, 2009
Association of Black Women Physicians Award for Medical Scholarship David Geffen School of Medicine, UCLA, 2004
Bixby Maternal Health Scholarship Recipient UC Berkeley, 2004
Max Factor Family Foundation Public Health Scholarship Recipient UC Berkeley, 2003
College of Letters and Science Honors Program UCLA, 2001
Cultural Psychology Research Award UCLA, 2000
Award for Excellence in Psychology 1998
Award for Excellence in Chemistry 1998
Join now to see all

PubMed

Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise-Authors' Reply.
Jessica K Jeffrey, Marc J Weintraub, Charles S Grob
Journal of the American Academy of Child and Adolescent Psychiatry. 2024-12-19
5 citations
Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.
Jessica K Jeffrey, Marc J Weintraub, Charles S Grob
Journal of the American Academy of Child and Adolescent Psychiatry. 2024-12-01
2 citations
Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.
Marc J Weintraub, Jessica K Jeffrey, Charles S Grob, Megan C Ichinose, R Lindsey Bergman
Psychedelic Medicine. 2023-12-01

Journal Articles

Anti-NMDA Receptor Encephalitis: Two Case Reports and a Review of Psychiatric Manifestations and Management
Kruse, J.L., Jeffrey, J.K., Davis, M.C., Dearlove, J., IsHak, W.W., Brooks, J.O., Annals of Clinical Psychiatry, 2/1/2014
Quality of life: the ultimate outcome measure of interventions in major depressive disorder
IsHak WW, Greenberg JM, Balayan K, Kapitanski N, Jeffrey J, Fathy H, Fakhry H, Rapaport MH, Harvard Review of Psychiatry, 9/1/2011
Effects of international health electives on medical student learning and career choice: results of a systematic literature review
Jeffrey J, Dumont RA, Kim GY, Kuo T, Fam Med, 1/1/2011
The role of dopaminergic agents in improving quality of life in major depressive disorder
IsHak WW, Davis M, Jeffrey J, Balayan K, Pechnick RN, Bagot K, Rapaport MH, Curr Psychiatry Rep, 12/1/2009
Overseas experience in global health: travels to Bhopal, India, 20 years after the Union Carbide disaster
Jeffrey J, Sztain J, Kuo T, Fam Med, 1/1/2008
The association between childhood asthma and community violence, Los Angeles County, 2000
Jeffrey J, Sternfeld I, Tager I, Public Health Rep, 11/1/2006
Community Violence as a predictor of childhood asthma hospitalization rates
Jeffrey, J, et al., Journal of Investigative Medicine, 1/1/2006
Join now to see all